Repurposing metformin for cancer treatment: current clinical studies

Young Kwang Chae(Northwestern University), Francis J. Giles(Northwestern University)

Oncotarget

March 19, 2016

10.18632/oncotarget.8194

Cited by 313

Related Papers

Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1–2 trials

|The Lancet Oncology|2019|537

Current landscape and future of dual anti-CTLA4 and PD-1/PD-L1 blockade immunotherapy in cancer; lessons learned from clinical trials with melanoma and non-small cell lung cancer (NSCLC)

|Journal for ImmunoTherapy of Cancer|2018|468

A Phase II Basket Trial of Dual Anti–CTLA-4 and Anti–PD-1 Blockade in Rare Tumors (DART SWOG 1609) in Patients with Nonpancreatic Neuroendocrine Tumors

|Clinical Cancer Research|2020|326

Mylotarg? (gemtuzumab ozogamicin) therapy is associated with hepatic venoocclusive disease in patients who have not received stem cell transplantation

|Cancer|2001|280

Epithelial-mesenchymal transition (EMT) signature is inversely associated with T-cell infiltration in non-small cell lung cancer (NSCLC)

|Scientific Reports|2018|258